Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Hearing Loss 2Tinnitus 1Ototoxicity 1Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Deafness 1

Interventions

sodium thiosulfate 2ebselen 2Ankle Brachial Index 2Acetylcysteine 2Tomography, X-Ray Computed 1Sodium Chloride 1Saline Solution 1Ringer's Lactate 1Platinum 1Ofloxacin 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Hyaluronic Acid 1Hearing Tests 1Hearing 1Ear Protective Devices 1Cisplatin 1Audiometry, Pure-Tone 1Atorvastatin 1Acoustic Impedance Tests 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hearing Loss × ebselen × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT01452607 2016-06-29

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Sound Pharmaceuticals, Incorporated

Phase 1 Completed
32 enrolled

Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡